Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells

Bone Marrow Transplantation

Volumn 22, Issue 7, 1998, Pages 625-630

  Hohaus, S ^a   Martin, H ^b   Wassmann, B ^b   Egerer, G ^a   Haus, U ^c   Farber L ^c   Burger, K J ^c   Goldschmidt, H ^a   Hoelzer, D ^b   Haas, R ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Novartis Pharma GmbH   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Autologous transplantation; G CSF; GM CSF; Mobilization; Peripheral blood stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOGRAFT; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INFLUENZA; LEUKAPHERESIS; LUNG TOXICITY; MALE; MOBILIZATION; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; VOMITING;

EID: 20244364500     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701422     Document Type: Article

References (28)

1. Gianni AM, Siena S, Bregni M et. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; I: 580-584.
2. Haas R, Hohaus S, Egerer G et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 1992; 9: 459-465.
3. Haas R, Murea S. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells. Cytok Mol Therapy 1995; 1: 249-270.
4. Winter JN, Lazarus HM, Rademaker A et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-286.
5. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-282.
6. Bolwell BJ, Goormastic M, Yanssens T et al. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14: 913-918.
7. Demuynck H, Delforge M, Verhoef G et al. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995; 90: 384-392.
8. Hohaus S, Goldschmidt H, Ehrhardt R, Haas R, Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 1993; 21: 508-514.
9. Pfreundschuh MG, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580-586.
10. Dreger P, Marquardt P, Haferlach T et al. Effective mobilis ation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993; 68: 950-957.
11. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131-1145.
12. Belosevic M, Davis CE, Meltzer MS, Nancy CA. Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. J Immunol 1988; 141: 890-896.
13. Cannistra SA, Vellenga E, Groshek P et al. Human granulocyte-macrophage colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 1988; 71: 672-676.
14. Heufler C, Koch F, Schuler G. Granulocyte-macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988; 167: 100-105.
15. Ho AD, Haas R, Wulf G et al. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma, Blood 1990; 75: 203-212.
16. Hohaus S, Haas R, Ogniben E et al. Imrnunological characterization of blood stem cell autografts collected under administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). In: Freund M, Link H, Weite K (eds). Cytokines in Hematopoiesis, Oncology, and AIDS. Springer Verlag: Berlin, Heidelberg, 1991.
17. Greenberg P, Advani R, Keating A et al. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 1996; 18: 10571064.
18. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
19. Menichella G, Pierelli L, Foddai ML et al. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol 1991; 79: 444-450.
20. Bensinger W, Appelbaum F, Rowley S el al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
21. Schneider JG, Crown JP, Wasserheit C et al. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. Bone Marrow Transplant 1994; 14: 877-884.
22. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
23. Demirer T, Buckner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
24. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
25. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
26. Haas R, Hohaus S, Goldschmidt H et al. High-dose therapy and autografting with peripheral blood stem cells in malignant lymphoma: granulocyte-macrophage colony-stimulating factor for stem cell mobilization. Semin Oncol 1994; 21 (Suppl. 16): 19-24.
27. + subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs a combinant of both. Exp Hematol 1996; 24: 1460-1468.
28. + peripheral blood stem cells for autografting in patients with breast cancer. Br J Haematol 1997; 97: 881-888.